Anti-SARS-CoV-2 cellular response after 2 and 3 doses of BNT162b2 mRNA vaccine in lymphoma patients receiving anti-CD20 antibodies

被引：4
|
作者：
Gressens, Simon B. [1 ]
Wiedemann, Aurelie [2 ,4 ]
Dechenaud, Marie [2 ]
Dupuis, Jehan [3 ]
Gallien, Sebastien [1 ,4 ]
Melica, Giovanna [1 ,4 ]
Haioun, Corinne [3 ,4 ]
Lemonnier, Francois [3 ,4 ]
Levy, Yves [1 ,2 ]
机构：
[1] Univ Paris Est Creteil, Hop Univ Henri Mondor, AP HP, Infect Dis & Immunol Dept, Creteil, France
[2] Univ Paris Est Creteil, Vaccine Res Inst, Fac Med, Team 16,INSERM U955, Creteil, France
[3] Grp Hosp Univ Chenevier Mondor, Serv Unite Hemopathies Lymphoides, IAP HP, F-94010 Creteil, France
[4] Univ Paris Est Creteil, INSERM, IMRB, F-94010 Creteil, France
来源：
VACCINE | 2023年 / 41卷 / 09期
关键词：
Third dose; COVID-19; Immunocompromised; Vaccine; T cell responses; Hematological malignancies; SARS-COV-2; IMMUNITY;
D O I：
10.1016/j.vaccine.2023.01.064
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Patients receiving anti-CD20 antibodies showed limited efficacy of a booster dose of BNT162b2. Patients with lymphomas combine such immunotherapies with cytotoxic chemotherapies that could result in an even greater alteration of the immune response to vaccination. We report here the impact of a third vac-cine dose on T cell specific responses in a small cohort of patients treated in our center by anti-CD20 ther-apies and cytotoxic chemotherapies for lymphoid malignancies. Our results showed that a third dose in these severely immune suppressed patients could improve the expansion on CD4+Th1+T cell responses while the effect CD8 + T cell responses was marginal. (c) 2023 Elsevier Ltd. All rights reserved.
引用
收藏
页码：1550 / 1553
页数：4
相关论文
共 50 条
  • [1] Anti-SARS-CoV-2 antibody response after 2 and 3 doses of BNT162b2 mRNA vaccine in patients with lymphoid malignancies
    Gressens, Simon B.
    Fourati, Slim
    Le Bouter, Anne
    Le Bras, Fabien
    Dupuis, Jehan
    Hammoud, Mohammad
    El Gnaoui, Taoufik
    Gounot, Romain
    Roulin, Louise
    Belhadj, Karim
    Haioun, Corinne
    Gallien, Sebastien
    Melica, Giovanna
    Lemonnier, Francois
    CLINICAL MICROBIOLOGY AND INFECTION, 2022, 28 (06) : 885.e7 - 885.e11
  • [2] Overview of Anti-SARS-CoV-2 Immune Response Six Months after BNT162b2 mRNA Vaccine
    Gandolfo, Claudia
    Anichini, Gabriele
    Mugnaini, Marco
    Bocchia, Monica
    Terrosi, Chiara
    Sicuranza, Anna
    Gori Savellini, Gianni
    Gozzetti, Alessandro
    Franchi, Federico
    Cusi, Maria Grazia
    VACCINES, 2022, 10 (02)
  • [3] Anti-SARS-CoV-2 IgG antibodies in patients with or without SARS-CoV-2 infection after BNT162b2 vaccine booster
    Salvagno, G. L.
    Henry, B. M.
    Lippi, G.
    INFECTIOUS DISEASES NOW, 2022, 52 (06): : 379 - 380
  • [4] Demographic and Clinical Factors Associated With Anti-SARS-CoV-2 Antibody Levels After 2 BNT162b2 mRNA Vaccine Doses
    Nam, Su Youn
    Jeon, Seong Woo
    Lee, Hyun Seok
    Lim, Hee Jeong
    Lee, Dong Wook
    Yoo, Seung Soo
    JAMA NETWORK OPEN, 2022, 5 (05) : E2212996
  • [5] Immunogenicity of three doses of anti-SARS-CoV-2 BNT162b2 vaccine in psoriasis patients treated with biologics
    Graceffa, Dario
    Sperati, Francesca
    Bonifati, Claudio
    Spoletini, Gabriele
    Lora, Viviana
    Pimpinelli, Fulvia
    Pontone, Martina
    Pellini, Raul
    Di Bella, Ornella
    Morrone, Aldo
    Cristaudo, Antonio
    FRONTIERS IN MEDICINE, 2022, 9
  • [6] Dynamics of humoral and cellular response to three doses of anti-SARS-CoV-2 BNT162b2 vaccine in patients with hematological malignancies and older subjects
    Laquintana, Valentina
    Mottini, Carla
    Marchesi, Francesco
    Marcozzi, Benedetta
    Terrenato, Irene
    Sperandio, Eleonora
    de Latouliere, Luisa
    Carrieri, Francesca
    Pimpinelli, Fulvia
    Pontone, Martina
    Pellini, Raul
    Campo, Flaminia
    Conti, Laura
    Accetta, Celeste
    Mandoj, Chiara
    Petrone, Fabrizio
    Di Bella, Ornella
    Vujovic, Branka
    Morrone, Aldo
    Compagnone, Mirco
    Principato, Eugenia
    Pinto, Eleonora
    Papa, Elena
    Falcucci, Paolo
    La Malfa, Antonia
    Pallocca, Matteo
    De Marco, Federico
    Piaggio, Giulia
    Ciliberto, Gennaro
    Mengarelli, Andrea
    di Martino, Simona
    FRONTIERS IN IMMUNOLOGY, 2024, 14
  • [7] Cellular immune response to the anti-SARS-CoV-2 BNT162b2 mRNA vaccine in pediatric autoimmune inflammatory rheumatic disease patients and controls
    Eviatar, Tali
    Pappo, Adi
    Freund, Tal
    Friedlander, Yishai
    Elkayam, Ori
    Hagin, David
    Heshin-Bekenstein, Merav
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2024, 217 (02): : 167 - 172
  • [8] Determining the best window for BNT162b2 mRNA vaccination for SARS-CoV-2 in patients with multiple sclerosis receiving anti-CD20 therapy
    Rico, Audrey
    Ninove, Laetitia
    Maarouf, Adil
    Boutiere, Clemence
    Durozard, Pierre
    Demortiere, Sarah
    Villarroel, Paola Mariela Saba
    Amroun, Abdennour
    Fourie, Toscane
    de Lamballerie, Xavier
    Pelletier, Jean
    Audoin, Bertrand
    MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2021, 7 (04)
  • [9] Safety and antibody response after one and/or two doses of BNT162b2 Anti-SARS-CoV-2 mRNA vaccine in patients treated by CAR T cells therapy
    Gastinne, Thomas
    Le Bourgeois, Amandine
    Coste-Burel, Marianne
    Guillaume, Thierry
    Peterlin, Pierre
    Garnier, Alice
    Imbert, Berthe-Marie
    Drumel, Thomas
    Mahe, Beatrice
    Dubruille, Viviane
    Blin, Nicolas
    Lok, Anne
    Touzeau, Cyrille
    Tessoulin, Benoit
    Jullien, Maxime
    Vanthygem, Sophie
    Bene, Marie C.
    Moreau, Philippe
    Le Gouill, Steven
    Chevallier, Patrice
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 196 (02) : 360 - 362
  • [10] Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors
    Barriere, J.
    Chamorey, E.
    Adjtoutah, Z.
    Castelnau, O.
    Mahamat, A.
    Marco, S.
    Petit, E.
    Leysalle, A.
    Raimondi, V.
    Carles, M.
    ANNALS OF ONCOLOGY, 2021, 32 (08) : 1053 - 1055
12345